INOVEMED (Micro Labs Pty Ltd)
Product name
INOVEMED
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
121 (255 working days)
Active ingredients
rufinamide
Registration type
New generic medicine
Indication
TRADENAME is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.